shutterstock_1335808664_nitpicker
nitpicker / Shutterstock.com
4 February 2021Big PharmaMuireann Bolger

Boehringer hits China’s Qilu with cancer drug patent suit

Chinese drug maker Qilu’s proposed generic version of a cancer treatment infringes three patents, according to a lawsuit filed by Boehringer Ingelheim.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
17 March 2020   The US Court of Appeals for the Federal Circuit has rescued one Boehringer Ingelheim patent, covering a type 2 diabetes treatment, from invalidation but affirmed a New Jersey district court’s cancellation of two others.
Big Pharma
11 February 2021   China has introduced new measures to enforce a patent linkage system and proposed draft rules on how a patent owner can challenge the approval of a drug.
Asia-Pacific
24 May 2022   The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.

More on this story

Big Pharma
17 March 2020   The US Court of Appeals for the Federal Circuit has rescued one Boehringer Ingelheim patent, covering a type 2 diabetes treatment, from invalidation but affirmed a New Jersey district court’s cancellation of two others.
Big Pharma
11 February 2021   China has introduced new measures to enforce a patent linkage system and proposed draft rules on how a patent owner can challenge the approval of a drug.
Asia-Pacific
24 May 2022   The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.

More on this story

Big Pharma
17 March 2020   The US Court of Appeals for the Federal Circuit has rescued one Boehringer Ingelheim patent, covering a type 2 diabetes treatment, from invalidation but affirmed a New Jersey district court’s cancellation of two others.
Big Pharma
11 February 2021   China has introduced new measures to enforce a patent linkage system and proposed draft rules on how a patent owner can challenge the approval of a drug.
Asia-Pacific
24 May 2022   The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.